Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2015

01-02-2015 | Breast Oncology

Nipple-Sparing Mastectomy in BRCA1/2 Mutation Carriers: An Interim Analysis and Review of the Literature

Authors: Katharine Yao, MD, Erik Liederbach, BS, Rong Tang, MD, Lan Lei, MD, Tomasz Czechura, MPH, Mark Sisco, MD, Michael Howard, MD, Peter J. Hulick, MD, David J. Winchester, MD, Suzanne B. Coopey, MD, Barbara L. Smith, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2015

Login to get access

Abstract

Background

There are few large-scale studies that have examined outcomes for BRCA1/2 carriers who have undergone nipple-sparing mastectomy (NSM). The objective of our study was to examine incidental cancers, operative complications, and locoregional recurrences in BRCA1/2 mutation carriers who underwent NSM for both risk reduction and cancer treatment.

Methods

This was a retrospective review of pathology results and outcomes of 201 BRCA1/2 carriers from two different institutions who underwent NSM from 2007 to 2014.

Results

NSM was performed in 397 breasts of 201 BRCA1/2 carriers. One hundred and twenty-five (62.2 %) patients had a BRCA1 mutation and 76 (37.8 %) had a BRCA2 mutation; 150 (74.6 %) patients underwent NSM for risk reduction and 51 (25.4 %) for cancer. Incidental cancers were found in four (2.7 %) of the 150 risk-reduction patients and two (3.9 %) of the 51 cancer patients. The nipple-areolar complex (NAC) was involved with cancer in three (5.8 %) patients. No prophylactic mastectomy had a positive NAC margin. There was loss of the NAC in seven breasts (1.8 %) and flap necrosis in ten (2.5 %) breasts. With a mean follow-up of 32.6 months (1–76 months), there have been four cancer events—three in cancer patients and one in a risk-reduction patient but none at the NAC.

Conclusion

NSM in BRCA1/2 carriers is associated with a low rate of complications and locoregional recurrence but these patients require long-term follow-up in both the cancer and risk-reduction setting.
Literature
1.
de Alcantara Filho P, Capko D, Barry JM, et al. Nipple-sparing mastectomy for breast cancer and risk reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol. 2011;18:3117–3122.PubMedCrossRef
2.
Wagner JL, Fearmonti R, Hunt KK, et al. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early stage breast cancer. Ann Surg Oncol. 2012;19:1137–1144.PubMedCrossRef
3.
Jensen JA, Orringer JS, Giuliano AE. Nipple sparing mastectomy in 99 patients with a mean follow up of 5 years. Ann Surg Oncol. 2011;18:1665–1670.PubMedCrossRef
4.
Harness JK, Vetter TS, Salibian AH. Areola and nipple-areola-sparing mastectomy for breast cancer treatment and risk reduction: report of an initial experience in a community hospital setting. Ann Surg Oncol. 2011;18:917–922.PubMedCentralPubMedCrossRef
5.
Crowe JP, Patrick RJ, Yetman RJ, Djohan R. Nipple sparing mastectomy update: one hundred forty nine procedures and clinical outcomes. Arch Surg. 2008; 146:1106–1110.CrossRef
6.
Warren Peled A, Foster RD, Stover AC, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012; 19:3402–3409.PubMedCrossRef
7.
Gerber B, Krause A, Dieterich M, Kundt G, Reimer T. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow up study. Ann Surg Oncol. 2009;249:461–468.CrossRef
8.
Kim HJ, Park EH, Lim WS, et al. Nipple areola skin sparing mastectomy with immediate transverse rectus abdominis musculocutaneous flap reconstruction is an oncologically safe procedure. Ann Surg. 2010;251:493–498.PubMedCrossRef
9.
Benediktsson KP, Perbeck L. Survival in breast cancer after nipple sparing subcutaneous mastectomy with immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol. 2008;34:143–148.PubMedCrossRef
10.
Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA 1 and 2 mutation carriers. J Clin Oncol. 2010;28:222–231.PubMedCentralPubMedCrossRef
11.
Antoniou A, Pharoah P, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA 1 and BRCA 2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130.PubMedCentralPubMedCrossRef
12.
Pierce LJ, Levin AM, Rebbeck TR, et al. Ten year multi-institutional results of breast conserving surgery and radiotherapy in BRCA1 and 2 associated stage I and II breast cancer. J Clin Oncol. 2006;24:2437–2443.PubMedCrossRef
13.
Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–2335.PubMedCrossRef
14.
Hartman LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84.CrossRef
15.
Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–164.PubMedCrossRef
16.
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055–1062.PubMedCrossRef
17.
Heemskerk-Gerritsen, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA 1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14:3335–3344.PubMedCentralPubMedCrossRef
18.
Reynolds C, Davidson JA, Lindor NM, et al. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved? Ann Surg Oncol. 2011;18:3102–3109.PubMedCrossRef
19.
Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014;21:37–41.PubMedCrossRef
20.
Colwell AS, Tessler O, Lin AM, et al. Breast reconstruction following nipple-sparing mastectomy: predictors of complications, reconstruction outcomes, and 5-year trends. Plast Reconstr Surg. 2014;133:496–506.PubMedCrossRef
21.
Spear SL, Willey SC, Feldman ED, et al. Nipple-sparing mastectomy for prophylactic and therapeutic indications. Plast Reconstr Surg.2011;128:1005–1014.PubMedCrossRef
22.
Algaithy ZK, Petit JY, Lohsiriwat V, et al. Nipple sparing mastectomy: can we predict the factors predisposing to necrosis? Eur J Surg Oncol. 2012;38:125–129.PubMedCrossRef
23.
Hartman LC, SellersTA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–1637.
24.
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–975.PubMedCentralPubMedCrossRef
25.
Sacchini V, Pinotti JA, Barros AC, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J Am Coll Surg. 2006;203:704–714.PubMedCrossRef
26.
Billar JA, Dueck AC, Gray RJ, Wasif N, Pockaj BA. Preoperative predictors of nipple-areola complex involvement for patients undergoing mastectomy for breast cancer. Ann Surg Oncol. 2011;18:3123–3128.PubMedCrossRef
27.
Stanec Z, Zic R, Budi S, et al. Skin and nipple-areola complex sparing mastectomy in breast cancer patients: 15-year experience. Ann Plast Surg. Epub 25 Dec 2013.
28.
Brachtel EF, Rusby JE, Michaelson JS, et al. Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol. 2009;27:4948–4954.PubMedCrossRef
29.
Simmons RM, Fish SK, Gayle L, et al. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann Surg Oncol. 1999;6:676–681.PubMedCrossRef
30.
Petit JY, Veronesi U, Rey P, et al. Nipple-sparing mastectomy: risk of nipple-areolar recurrences in a series of 579 cases. Breast Cancer Res Treat. 2009;114:97–101.PubMedCrossRef
31.
Coopey SB, Tang R, Lei L, et al. Increasing eligibility for nipple-sparing mastectomy. Ann Surg Oncol. 2013;20:3218–3222.PubMedCrossRef
Metadata
Title
Nipple-Sparing Mastectomy in BRCA1/2 Mutation Carriers: An Interim Analysis and Review of the Literature
Authors
Katharine Yao, MD
Erik Liederbach, BS
Rong Tang, MD
Lan Lei, MD
Tomasz Czechura, MPH
Mark Sisco, MD
Michael Howard, MD
Peter J. Hulick, MD
David J. Winchester, MD
Suzanne B. Coopey, MD
Barbara L. Smith, MD, PhD
Publication date
01-02-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3883-3

Other articles of this Issue 2/2015

Annals of Surgical Oncology 2/2015 Go to the issue

Colorectal Cancer

Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial

Colorectal Cancer

Clinical Significance of Thrombocytosis Before Preoperative Chemoradiotherapy in Rectal Cancer: Predicting Pathologic Tumor Response and Oncologic Outcome

Endocrine Tumors

Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer

Melanomas

In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy

Breast Oncology

Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy

Thoracic Oncology

Benefit of Adjuvant Chemotherapy After Resection of Stage II (T1-2N1M0) Non-Small Cell Lung Cancer in Elderly Patients